Apricus Biosciences (APRI +4.5%) holds on to gains late in the day, after receiving FDA approval...

|About: Apricus Biosciences, Inc (APRI)|By:, SA News Editor

Apricus Biosciences (APRI +4.5%) holds on to gains late in the day, after receiving FDA approval for its anti-fungal OTC drug Tolnaftate-D, containing the company's NexACT technology.